Abstracts
HM4 THE IMPACT OF A PHARMACIST-PROVIDED TELEPHONE MEDICATION THERAPY MANAGEMENT PROGRAM ON MEDICATION AND HEALTH-RELATED PROBLEMS, MEDICATION ADHERENCE, AND TOTAL DRUG COSTS AMONG MEDICARE BENEFICIARIES: A 6-MONTH FOLLOW-UP
Moczygemba LR yg 1 , Barner JC 2 , Lawson KA 2 , Brown CM 2 , Gabrillo E 3 , Godley PJ 4 , Johnsrud M 2 1 Virginia Commonwealth University, Richmond, VA, USA, 2 University of Texas at Austin, Austin, TX, USA, 3 Scott and White Health Plan, Temple, TX, USA, 4 Scott and White Health System, Temple, TX, USA OBJECTIVES: To determine if differences existed between the intervention group [after participating in a pharmacist-provided telephone medication therapy management (PPMTM) program] and the control group in: 1) Medication/health-related problems (MHRPs); 2) Medication adherence; and 3) Total Part D drug costs. METHODS: This quasi-experimental study of Part D benefi ciaries from a Texas health plan used the Andersen Model as its theoretical framework. Predisposing factors were age, gender, and race; need factors were number of medications, number of chronic diseases and medication regimen complexity. The intervention and control groups were matched on number of medications and number of chronic diseases. The health behavior was PPMTM participation. Outcomes were changes in: 1) Number of MHRPs; 2) Medication adherence using medication possession ratio (MPR); and 3) Total drug costs. Multivariate regression was used for group comparisons of outcomes. RESULTS: The intervention (n 60) and control (n 60) groups were not statistically different in predisposing or need factors except for gender (intervention 51.7% male; control 28.3% male; p 0.009). At baseline, 4.8 ( 2.7) MHRPs were identifi ed in the intervention group and 9.2 ( 2.9) in the control group. At the 6-month follow-up, 2.5 ( 2.0) and 7.9 ( 3.0) MHRPs remained, respectively. Multivariate regression revealed that the intervention group had signifi cantly more MHRPs resolved (p 0.0003) when compared to the control group, while controlling for predisposing and need factors. There were no other signifi cant predictors of MHRP resolution, Analyses showed no signifi cant predictors of change in MPR or total drug costs from baseline to 6-month follow-up. CONCLUSIONS: A telephone MTM program was effective in resolving MHRPs among Medicare benefi ciaries; however, no signifi cant differences existed between the intervention and control groups in medication adherence and total drug costs. A total of 1,888,682 patients met our inclusion criteria. Mean age ( SD) was 71.6 ( 11.6) years, 59.5% were female, and 66.4% were white. Approximately 58.9%, 5.8%, 0.5% had coexisting hypertension, nephropathy, and hypertension nephropathy. Overall, 56.9% were receiving ACEI/ARB therapy. Logistic regression indicated that patients with coexisting hypertension nephropathy and hypertension were 72% and 36% more likely to use ACEI/ARB compared to patients without hypertension and/or nephropathy. However, patients with nephropathy were 24% less likely to receive ACEI/ARB therapy. Females, older patients, and patients of nonwhite races were also more likely to use ACEI/ARB. Patients with myocardial infarction, sleep apnea, coronary artery disease, retinopathy or heart failure were more likely to have used ACEI/ARB, while the opposite was true for those with hypercholesterolemia, peripheral vascular, cerebrovascular, or chronic obstructive pulmonary diseases. All results were statistically signifi cant at P .0001 level. CONCLUSIONS: Less than 60% of Medicare Part D enrollees with diabetes received ACEI/ARB therapy. Several patient characteristics can predict ACEI/ARB use. Opportunities exist for qualityimprovement interventions that could increase the outcomes for high-risk patients.
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Chambers J J 1 , Neumann PJ 2 , Buxton MJ 3 1 Mapi Values, Boston, MA, USA, 2 Tufts Medical Center, Boston, MA, USA, 3 Brunel University, Uxbridge, Middlesex, UK OBJECTIVES: Despite the huge cost of the program, the Centers for Medicare and Medicaid Services (CMS) maintains that cost-effectiveness is not considered in national coverage determinations (NCDs) for medical technologies. Our objective was to assess the cost-effectiveness of technologies and interventions that are the subject of Medicare NCDs in order to investigate whether an implicit cost-effectiveness threshold exists. In addition, we explored whether CMS have cited cost-effectiveness evidence in NCDs. METHODS: We reviewed NCD decision memos from 1999 through 2007 (n 103). A literature review was conducted for each coverage decision to fi nd relevant economic evaluations. The economic evaluation that best represented each coverage decision was included in a review of the cost-effectiveness of medical technologies considered in NCDs. RESULTS: Sixty-four coverage decisions were identifi ed from 103 decision memos. Fifty were associated with a positive coverage decision and 14 with a
